TP-04 (topical lotilaner)
Papulopustular Rosacea
Phase 2aCompleted
Key Facts
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a public biopharma company that achieved a significant milestone with the 2023 FDA approval of XDEMVY for Demodex blepharitis, a common eyelid disease affecting millions. The company is now executing its commercial launch while advancing a pipeline of novel candidates, including TP-03 for Meibomian Gland Disease and TP-04 for rosacea, based on its targeted therapeutic approach. Tarsus's strategy is to identify and develop treatments for prevalent, underserved conditions, aiming to establish a leading position in medical dermatology and ophthalmology.
View full company profileTherapeutic Areas
Other Papulopustular Rosacea Drugs
| Drug | Company | Phase |
|---|---|---|
| Epsolay® (benzoyl peroxide) cream | Sol-Gel Technologies | Approved |
| BTX 1702 | Botanix Pharmaceuticals | Pre-clinical / Early Development |